Gyre Therapeutics
GYRE
Gyre Therapeutics (GYRE) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- $0.03
- EPS estimate
- $0.05
- EPS surprise
- −35.76%
- Revenue surprise
- −7.18%
- Revenue
- $30.6M
- Revenue estimate
- $32.9M
- Reported
- Nov 7, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 7, 2025 | $0.05 | $0.03 | −35.76% | $30.6M | SEC |
| Q2 2025 | Aug 11, 2025 | $0.03 | $0.00 | −100.00% | $26.8M | SEC |
| Q1 2025 | May 9, 2025 | $0.03 | $0.00 | −100.00% | $22.1M | SEC |
| Q4 2024 | Feb 18, 2025 | $0.04 | $0.00 | −100.00% | $27.9M | SEC |
| Q3 2024 | Nov 13, 2024 | $0.00 | $0.01 | +0.00% | $25.5M | SEC |
| Q2 2024 | Aug 13, 2024 | $0.00 | $0.01 | +0.00% | $25.2M | SEC |
| Q1 2024 | May 9, 2024 | $0.00 | $0.03 | +0.00% | $27.2M | SEC |
| Q2 2023 | Aug 14, 2023 | −$1.05 | −$1.05 | +0.00% | $0.00 | SEC |
| Q4 2022 | Mar 30, 2023 | −$1.58 | −$19.05 | −1109.52% | $0.00 | SEC |
| Q2 2022 | Aug 15, 2022 | −$3.68 | $24.60 | +769.39% | $0.00 | SEC |
| Q1 2022 | May 9, 2022 | −$6.85 | −$6.90 | −0.73% | $794,000.00 | SEC |
| Q4 2021 | Mar 31, 2022 | −$8.81 | −$9.75 | −10.64% | $2.4M | SEC |
| Q3 2021 | Nov 12, 2021 | −$9.90 | −$12.00 | −21.21% | $2.3M | SEC |
| Q2 2021 | Aug 5, 2021 | −$10.43 | −$9.60 | +7.91% | $1.1M | SEC |
| Q1 2021 | May 6, 2021 | −$8.66 | −$11.85 | −36.80% | $1.5M | SEC |
| Q4 2020 | Mar 4, 2021 | −$12.94 | −$12.90 | +0.29% | $2.0M | SEC |
| Q3 2020 | Nov 5, 2020 | −$12.10 | −$10.95 | +9.50% | $893,000.00 | SEC |
| Q2 2020 | Aug 6, 2020 | −$12.94 | −$14.40 | −11.30% | $1.7M | SEC |
| Q1 2020 | May 11, 2020 | −$5.48 | −$4.20 | +23.29% | $16.4M | — |
Quarterly revenue
Frequently asked questions
When did Gyre Therapeutics (GYRE) last report earnings?
Gyre Therapeutics last reported on Nov 7, 2025, covering fiscal Q3 2025.
Did GYRE beat earnings estimates?
No. Gyre Therapeutics reported EPS of $0.03 for Q3 2025 against a $0.05 estimate — a 35.76% miss.
How much revenue did GYRE report last quarter?
Gyre Therapeutics reported $30.6M in revenue for Q3 2025, against a consensus estimate of $32.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.